Key result
Possible sarcopenia was associated with an increased risk of developing new-onset multimorbidity over 3 years compared to no sarcopenia (HR 1.19; 95% CI 1.03-1.38).
Why the study?
Little is known about the association between sarcopenia and multimorbidity among middle-aged and older adults.
Is sarcopenia associated with the development of multimorbidity in middle-aged and older adults?
Observational (n=12,760)
Yes
Is sarcopenia associated with the development of multimorbidity in middle-aged and older adults?
Hazard Ratio: 1.19 (95% CI 1.03–1.38)
Possible sarcopenia is a significant predictor for the development of multimorbidity in middle-aged and older Chinese adults, suggesting a role for early health screening.
Sarcopenia may flag higher multimorbidity risk in middle-aged Chinese adults; leaves open whether screening or treatment modifies outcomes.
BACKGROUND: Little is known about the association between sarcopenia and multimorbidity among middle-aged and older adults. This study investigated whether sarcopenia is associated with multimorbidity in middle-aged and older Chinese individuals. MATERIALS AND METHODS: A total of 12,760 participants from China Health and Retirement Longitudinal Study (CHARLS) 2015, with data on 14 specified chronic diseases and sarcopenia status were included in the cross-sectional analysis. A total of 7345 participants without multimorbidity from the CHARLS 2015 were included and followed up in 2018 in the longitudinal analysis. Logistic regression models were used in a cross-sectional investigation to assess the association between sarcopenia status and multimorbidity. In a longitudinal analysis, the relationships between sarcopenia status and multimorbidity were investigated using Cox proportional hazards models. RESULTS: Multimorbidity was prevalent in the no sarcopenia, possible sarcopenia, and sarcopenia groups at 38.8 % (3765/9713), 56.6 % (1199/2118), and 48.5 % (451/929), respectively. Multivariable regression revealed that both possible sarcopenia (β = 0.088, P<0.001) and sarcopenia (β = 0.028, P = 0.009), contributed to the number of chronic diseases. Logistic regression revealed that possible sarcopenia (OR: 1.56, 95 % CI: 1.39-1.76) was associated with multimorbidity. In the longitudinal analysis, participants in the possible sarcopenia group (HR: 1.19, 95 % CI:1.03-1.38) were more prone to experience new onset multimorbidity than did participants in the no sarcopenia group. CONCLUSIONS: Possible sarcopenia is associated with the development of multimorbidity in middle-aged and older Chinese populations. Health screening of populations with possible sarcopenia can facilitate early detection of multimorbidity.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2023) conducted an observational in Multimorbidity and sarcopenia (n=12,760). Possible sarcopenia vs. No sarcopenia was evaluated on New onset multimorbidity (HR 1.19, 95% CI 1.03-1.38). Possible sarcopenia was associated with an increased risk of developing new-onset multimorbidity over 3 years compared to no sarcopenia (HR 1.19; 95% CI 1.03-1.38).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: